SBStephan Brackmann

Stephan Brackmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stephan Brackmann has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Colonic Mucosal Gene Expression Profile in Patients with Neoplastic Progression in Longstanding Ulcerative Colitis

    by Lene Alsøe, Stephan Andreas Brackmann, Yohan Lefol, Anna Berit Wennerström, Yan Liu, Rosa Ana Risques, Solveig Norheim Andersen, Hilde Loge Nilsen

    Purpose: Long-standing mucosal inflammation is suspected to be one of the main drivers of colitis-associated colorectal cancer (CA-CRC), but far from all colitis patients develop cancer. Non-neoplastic mucosa located distant from neoplastic lesions may harbour early molecular events of carcinogenesis. We hypothesise that patients with UC who have progressed to neoplasia (progressors) exhibit a distinct molecular profile of mucosal inflammation from non-progressors. Patients and Methods: We performed transcriptomic profiling of 143 mucosal biopsies from non-neoplastic colonic segments of 14 UC progressors and 30 UC non-progressors using the Agilent SurePrint G3 human gene expression 60K microarray. Subsequently, we carried out gene set ontology analyses. In addition, we assessed lymphocyte infiltration to the mucosa of biopsies taken adjacent to biopsies used for transcriptomic analysis by immunohistochemistry. Results: Adjusting for molecular alterations associated with long disease duration, our findings revealed that UC Progressors’ inflamed mucosa has a distinct gene expression profile of 529 significantly deregulated genes, eg LTB, CXCL13, CD19, C3 and CYP4F3. The profile was negatively enriched for biological processes (BPs) such as adaptive immune responses and complement system activity and positively enriched for processes related to detoxification. The negatively enriched BPs were supported by the presence of fewer infiltrating B cells and less lymphoid aggregates in the microenvironment of the inflamed mucosa of progressors. Conclusion: The inflamed colonic mucosa from UC patients who have progressed to dysplasia or cancer has a different gene expression profile than that of UC non-progressors, suggesting lower levels of lymphoid organ-initiating and immune cell-attracting signals and fewer infiltrating immune cells to the mucosa. Consequently, progressors may lack the ability to mount sufficient adaptive immune responses necessary to counteract driving forces of malignant transformation in UC.


  • 863 Stool DNA Markers for the Detection of Neoplasia in Patients With Longstanding Inflammatory Bowel Disease

    by Pasquale Klepp, Hatim T. Allawi, Milada C. Smastuen, Lars Gustav. Lyckander, Arne Røseth, Solveig N. Andersen, Anita Tollisen, Graham P. Lidgard, Tamara Sander, Bjorn Moum, et al.


  • Su1179 Reproducibility of Serologic Antibody Activity At Diagnosis and After Treatment in Ulcerative Colitis (UC) and Crohn's Disease (CD). A Prospective Population Based Study

    by Trond E. Detlie, Petr Ricanek, Milada Cvancarova, Christine Olbjørn, Gøri Perminow, Stephan Brackmann, Andreas Rydning, Morten H. Vatn


  • Large Scale Genomic Instability in Patients With Colorectal Cancer in Inflammatory Bowel Disease. Association With Clinicohistological Factors and Survival

    by Stephan Brackmann, Maria E. Pretorius, Solveig N. Andersen, Frøydis Langmark, Ole P.F. Clausen, Morten H. Vatn, Havard E. Danielsen

  • Paucity of mycobacteria in mucosal bowel biopsies from adults and children with early inflammatory bowel disease.

    by Petr Ricanek, Sheba M. Lothe, Irena Szpinda, Anne T. Jorde, Stephan Brackmann, Gøri Perminow, Kristin K. Jørgensen, Andreas Rydning, Morten H. Vatn, Tone Tønjum

    The presence of Mycobacterium avium subspecies paratuberculosis (MAP) has previously been inferred in the genesis of Crohn's disease (CD), and a higher incidence of MAP PCR positivity has been demonstrated in the gut and peripheral blood of CD patients than in healthy individuals. The objective of this prospective study was to assess the potential etiological role of MAP in the pathogenesis of CD.


  • Open Access

    Widespread but not localized neoplasia in inflammatory bowel disease worsens the prognosis of colorectal cancer

    by Stephan Brackmann, Geir Aamodt, Solveig Norheim Andersen, Borghild Roald, FrφYdis Langmark, Ole P.F. Clausen, Erling Aadland, Olav Fausa, Andreas Rydning, Morten H. Vatn

    Background. Patients with inflammatory bowel disease (IBD) are at increased risk of colorectal cancer (CRC). Recently, new phenotypes of CRC in IBD have


  • M2000 Widespread But Not Localized Neoplasia in IBD Worsens the Prognosis of CRC

    by Stephan Brackmann, Geir Aamodt, Solveig Norheim Andersen, Borghild Roald, Frøydis Langmark, Ole P.F. Clausen, Erling Aadland, Andreas Rydning, Morten H. Vatn

  • Two distinct groups of colorectal cancer in inflammatory bowel disease

    by Stephan Brackmann, Solveig Norheim Andersen, Geir Aamodt, Borghild Roald, Frydis Langmark, Ole P.F. Clausen, Erling Aadland, Olav Fausa, Andreas Rydning, Morten H. Vatn

    The histological variability in colitis-associated colorectal cancer (CRC in inflammatory bowel disease [IBD]) and the association to clinical factors is unknown. In population-based material including 67 patients with CRC in IBD, histopathology of the cancers and tissue samples from different colorectal localizations were reevaluated, and relationships to clinical factors analyzed. Forty-three of 60 patients (75%) showed dysplasia in the colorectum apart from the cancer, while 17 (25%) had no dysplasia at cancer diagnosis. Mean age at onset of IBD was 22 years in patients with and 34 years in patients without dysplasia (P = 0.01). The mean duration of colitis-CRC interval was 21 years in patients with and 16 years in patients without dysplasia (P = 0.02). The latter group included all patients with a colitis-CRC interval <10 years. Active inflammation was more likely to occur in patients with dysplasia (odds ratio [OR] 4.2). The 2 groups were not discriminated by gender, family history of CRC or IBD, diagnosis of PSC, medical treatment, active symptoms, or histological features like type of cancer and differentiation. In multiple logistic regression analysis the age at onset of IBD was the strongest predictive variable for dysplasia at cancer diagnosis (P = 0.025). Widespread neoplasia occurs in the majority of cases with CRC in IBD and is associated with early onset of IBD. Localized neoplasia occurs in about a quarter of the patients and shows an association with late-onset IBD. The 2 groups probably represent different pathogenetic entities of neoplasia in IBD. This might have consequences for surveillance strategies.


  • Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease

    by Stephan Brackmann, Solveig N. Andersen, Geir Aamodt, Frøydis Langmark, Ole P. F. Clausen, Erling Aadland, Olav Fausa, Andreas Rydning, Morten H. Vatn

    Objective. Inflammatory bowel disease (IBD) is associated with an increased risk of colorectal cancer (CRC), but more knowledge is needed about the possible relationship between clinical parameters and the time to development of cancer in IBD. The aim of the study was to determine the variability of the colitis-CRC interval and to analyze the association with clinical variables in an attempt to gain information on predictive factors of time to cancer within a relatively large cohort of CRC patients. Material and methods. Patients diagnosed with IBD prior to 1 May 2005 at three university hospitals in Oslo were matched against the CRC files at the Cancer Registry of Norway. Only histological re-confirmed IBD and adenocarcinoma of the colorectum were included. Results. Sixty-one patients with CRC in ulcerative colitis and 6 in Crohn's disease, including 13 CRC in primary sclerosing cholangitis (PSC), covering a follow-up of 1625 patient years, were identified. The median time from diagnosis of IBD to CRC was 17 years. Seven of 58 patients (12%) developed CRC within 10 years from onset of IBD symptoms and 14/67 (21%) within 10 years after the diagnosis of IBD. The colitis-CRC interval decreased by a factor of 0.154 (p=0.018) when age at onset of IBD increased by one year. Mean age at onset of IBD was 30 years in patients with Dukes’ stage C or D compared with 20 years in Dukes’ stage A or B patients (p=0.017). The colitis-CRC interval decreased by a factor of 0.138 (p=0.003) when the percentage of the colitis-CRC interval with active symptoms increased by 1%. Patients with PSC were significantly younger at onset of IBD symptoms (+PSC: 19 years versus no PSC:29 years, p=0.04), but the colitis-CRC interval was similar to IBD without PSC (17 years versus 20 years, p=0.236). Mean duration of the colitis-CRC interval was not related to family history or drug consumption prior to CRC. Conclusions. In the present cohort, for whom the median time from diagnosis of IBD to CRC was 17 years, 21% of the cancers developed before 10 years of disease, which is before colonoscopic screening is usually recommended. High age at onset of IBD may be related to a more aggressive development of CRC in IBD and early inclusion in screening programs might be considered for this group of patients. Symptom activity but not the diagnosis of PSC, family history of CRC or IBD or drug treatment seems to have an effect on the colitis-CRC interval.